A prognostic index for multiple myeloma

British Journal of Cancer

Volumn 73, Issue 9, 1996, Pages 1101-1107

  Grignani, G ^a   Gobbi, P G ^a   Formisano, R ^a   Pieresca, C ^a   Ucci, G ^a   Brugnatelli, S ^a   Riccardi, A ^a   Ascari, E ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Histopathology; Multiple myeloma; Prognosis; Response to treatment; Staging system

Indexed keywords

MELPHALAN; PEPTICHEMIO; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

EID: 0029988747     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.212     Document Type: Article

References (54)

1. AKAIKE H. (1974). A new look at the statistical model identification. IEEE Trans. Automat. Contr., 19, 716-723.
2. ALEXANIAN R AND DIMOPOULOS M. (1994). The treatment of multiple myeloma. N. Engl. J. Med., 330, 484-489.
3. ALEXANIAN R, DIMOPOULOS M, SMITH T, DELASALLE K, BARLOGIE P AND CHAMPLIN R. (1994). Limited value of myeloablative therapy for late multiple myeloma. Blood, 83, 512-516.
4. ARMITAGE P, AND BERRY G. (1987). Statistical Methods in Medical Research. Blackwell Scientific Publications: Oxford.
5. ATTAL M, HUGUET F, SCHLAIFER D, PAYEN C, LAROCHE M, FOURNIE B, MAZIERES B, PRIS J AND LAURENT G. (1992). Intensive combined chemotherapy for previously untreated aggressive myeloma. Blood, 79, 1130-1136.
6. BARTL R. (1988). Histologic classification and staging of multiple myeloma. Hematol. Oncol., 6, 107-113.
7. BARTL R, FRISCH B, BURKHARDT R, FATEH-MOGHADAM A, MAHL G, GIERSTER P, SUND M AND KETTNER G. (1982). Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br. J. Haematol., 51, 361-375.
8. BATAILLE R, BOCCADORO M, KLEIN B, DURIE B AND PILERI A. (1992). C-reactive protein and b-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.
9. BLADÈ J, SAN MIGUEL JF, ALCALÀ A. MALDONADO J, SANZ MA, GARCIA-CONDE J, MORO MJ, ALONSO C, BESALDUCH J, ZUBIZARRETA A, BESSES C, GONZALES-BRITO G, HERNANDEZ-MARTIN J, FERNADEZ-CALVO J, RUBIO D, ORTEGA F, JIMENEZ R, COLOMINAS P, FAURA MV, FONT L, TORTOSA J, DOMINGO A, FONTANILLAS M, ROZMAN C AND ESTAPÉ J. (1993). Alternating combination VCMP/VBAP chemotherapy versus Melphalan/Prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J. Clin. Oncol., 11, 1165-1171.
10. BUGLIOSI R, TRIBALTO M, AVVISATI G, BOCCADORO M, DE MARTINIS C, FRIERA R, MANDELLI F, PILERI A, PAPA G. (1994). Classification of patients affected by multiple myeloma using a neural network software. (letter) Eur. J. Haematol., 52, 182-183.
11. CALIGARIS-CAPPIO F, BERGUI L, TESIO L, PIZZOLO G, MALAVASI F, CHILOSI M, CAMPANA D, VAN CAMP B AND JANNOSSY G. (1985). Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J. Clin. Invest., 76, 1243-1251.
12. CALIGARIS-CAPPIO F, GREGORETTI MG, GHIA P AND BERGUI L. (1992). In vitro growth of human multiple myeloma: implications for biology and therapy. Hematol. Oncol. Clin. North. Am., 6, 257-271.
13. CARTER A, HOCHERMAN I, LINN S, COHEN Y AND TATARSKY I. (1987). Prognostic significance of plasma cell morphology in multiple myeloma. Cancer, 60, 1060-1065.
14. COHEN HJ, BARTOLUCCI AA, FORMAN WB AND SILBERMAN HR FOR THE SOUTHERN CANCER STUDY GROUP. (1986). Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J. Clin. Oncol., 4, 888-899.
15. COOPER MR, MCINTYRE OR, PROPERT KJ, PROPERT KJ, KOCHWA S, ANDERSON K, COLEMAN M. KYLE RA, PRAGER D, RAFLA S AND ZIMMER B. (1986). Single, sequential and multiple alkylating agent therapy for multiple myeloma: a Cancer and Leukemia Group B experience. J. Clin. Oncol., 4, 1331-1339.
16. COX D. (1972). Regression models and life-tables (with Discussion). J. R. Star. Soc., 34, 187-220.
17. CUNNINGHAM D, PAZ-ARES L, MILAN S, POWLES R, NICOLSON M. HICKISH T, SELBY P, TRELEAVAN J, VINER C, MALPAS J, FINDLAY M, RAYMOND J AND GORE ME. (1994). High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol., 12, 759-763.
18. DIMOPOULOS MA, ALEXANIAN R, PRZEPIORKA D, HESTER J, ANDERSSON P, GIRALT S, MEHRA R, VAN BESIEN K, DELASALLE KB, READING C, DEISSEROTH AB AND CHAMPLIN RE (1993). Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood, 82, 2324-2328.
19. DREWINKO B, ALEXANIAN R, BOYER H, BARLOGIE B AND RUBINOW SI. (1981). The growth fraction of human myeloma. Blood, 57, 333-338.
20. DURIE BGM AND SALMON SE. (1975). A clinical staging system for multiple myeloma. Cancer, 36, 842-854.
21. EPSTEIN J, XIAO H AND HE XY. (1990). Markers of multiple haematopoietic-cell lineage in multiple myeloma. N. Engl. J. Med., 322, 664-668.
22. FERNAND JP, CHEVRET S, RAVAUD P, DIVINE M, LEBLOND V, DREYFUS F, MARIETTE X AND BROUET JC (1993). High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood. 82, 2005-2009.
23. FRITZ E, LUDWIG H AND KUNDI M. (1984). Prognostic relevance of cellular morphology in multiple myeloma. Blood, 63, 1072-1079.
24. GAHRTON G, TURA S, LJUNGMAN P, BELANGER C, BRANDT L, CAVO M, FACON T, GRANENA A, GORE M, GRATWOHL A, LOWENBERG B, NIKOSKEEAINEN J, REIFFERS JJ, SAMSON D, VERDONCK L AND VOLIN L. (1991). Allogeneic bone marrow transplantation in multiple myeloma. N. Engl. J. Med., 325, 176-179.
25. GOBBI PG, BERTOLONI D, GRIGNANI G, PIERESCA C, ROSSI A, RUTIGLIANO L, MERLINI G, RICCARDI A AND ASCARI E. (1991). A plea to overcome the concept of 'staging' and related inadequacy in multiple myeloma. Eur. J. Haematol., 46, 177-181.
26. GOLDIE JH AND COLDMAN AJ. (1979). A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat. Rep., 63, 1727-1733.
27. GORE ME, SELBY PJ, VINER C, CLARCK PI, MELDRUM M, MILLAR B, BELL J, MAITLAND JA, MILAN S, JUDSON IR, ZUIABLE A, TILLYER C, SLEVIN M, MALPAS JS AND MCELWAIN TJ. (1989). Intensive treatment of multiple myeloma and criteria for complete remission. Lancet, 2, 879-882.
28. GREGORY WM, RICHARDS MA AND MALPAS JS. (1992). Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol., 10, 334-342.
29. GREIPP PR. (1992). Advances in the diagnosis and management of myeloma. Semin. Hematol., 29 (suppl. 2), 24-45.
30. GREIPP PR, RAYMOND NM, KYLE RA AND O'FALLON WM. (1985). Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood, 65, 305-310.
31. GUILLEMIN F, GUERCI A-P, FEUGIER P, PÉRÉ P, POUREL J AND GUERCI O. (1995). Development of a criterion for response to therapy at 6 months in multiple myeloma. Eur. J. Haematol., 55, 110-116.
32. HAROUSSEAU JL, MILPIED N, LAPORTE JP, COLLOMBAT P, FACON T, TIGAUD JD, CASASSUS P, GUILHOT F, IRFRAH N AND GANDHOUR C. (1992). Double-intensive therapy in high-risk multiple myeloma. Blood, 79, 2827-2833.
33. JAGANNATH S, BARLOGIE B, DICKE K, ALEXANIAN R, CHESON B, LEMAISTRE FC, SMALLWOOD L, PRUITT K AND DIXON DO. (1990). Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood, 76, 1860-1866.
34. JOHNSON PWM AND SELBY PJ. (1994). The treatment of multiple myeloma an important MRC trial. Br. J. Cancer, 70, 781-785.
35. KAPLAN EL AND MEIER P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
36. KOTASEK D, SHPHERD KM, SAGE RE, DALE BM, NORMAN JE, CHARLES P, GREGG A, PILLOW A AND BOLTON A. (1992). Factors affecting blood stem cell collections following high-dose cyclophosphamide in lymphoma, myeloma and solid tumors. Bone Marrow Transplant., 9, 11-17.
37. KUBAGAWA H, VOGLER LB, CAPRA JD, CONRAD ME AND LAWTON AR. (1979). Studies of the clonal origin of multiple myeloma. J. Exp. Med., 150, 792-807.
38. KYLE RA. (1993). Newer approaches to the management of multiple myeloma. Cancer, 72, 3489-3494.
39. LONGO DL. (1994). Plasma cell disorders. In Harrison's Principle of Internal Medicine, XIII. Isselbacher KJ, Braunwald E, Wilson GD, Martin JB, Fauci AS and Kasper DL. (eds) pp. 1618-1625. McGraw-Hill: New York.
40. MACLENNAN IC, KELLY K, CROCKSON RA, COOPER EH, CUZICK J AND CHAPMAN C. (1988). Results of the MRC myelomatosis trials for patients entered since 1980. Hematol. Oncol., 6, 145-158.
41. MEDICAL RESEARCH COUNCIL'S WORKING PARTY ON LEUKEMIA IN ADULTS. (1980). Prognostic features in the third MRC myelomatosis trial. Br. J. Cancer. 42, 831-840.
42. MERLINIG, WALDENSTROM JG AND JAYAKAR SD. (1980). A new improved clinical staging system for multiple myeloma based on the analysis of 123 treated patients. Blood, 55, 1011-1019.
43. MORO MS, PORTERO JA, GASCON A, HERNANDEZ JM, ORTEGA F, JIMENEZ R, GUERRAS L, MARTINEZ M, CASANOVA F, SANZ MA, GONZALES MZ AND SAN MIGUEL JE. (1992). Utility of the examination of plasma cell morphology in the study of multiple myeloma. Sangre, 37, 175-179.
44. NIKSVZKY R, SIEGEL D AND MICHAELI J. (1993). Biology and treatment of multiple myeloma. Blood Rev., 7, 24-33.
45. PASQUALETTI P, CASALE R, COLLACIANI A, ABRUZZO BP AND COLANTUONO D. (1990). Multiple myeloma: relationship between survival and cellular morphology. Am. J. Heamtol., 33, 145-147.
46. PAULE B, QUILLARD J, BISSON M, KAHN MF AND MASSIAS P. (1988). Prognostic significance of plasma cell morphology in multiple myeloma. Nouv. Rev. Fr. Hematol., 30, 209-212.
47. PAVLOVSKY S, CORRADO C, SANTARELLI MT, SASLAVSKY J, CAVAGNARO F, PALAU M, DE TAZANOS-PINTO M, HUBERMAN A AND LEIN JM. (1988). An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combination: an Argentine group for the treatment of acute leukemia study. J. Clin. Oncol., 6, 769-775.
48. PEEST D, COLDEWEY R, DEICHER H, SAILER M, VYKOUPIL C, LEO R. GEORGH A, KAROW J, HOEPPNER E, DIEHL V, ESSERS U, GAMM H, GLÜCK S, GÖRG K, GRAMATZKI M, HAUSWALDT C, HEILMANN E, HIFMEYER V, KEYSERLINGK HJ, KINDLER A, OERTEL J, PLANKER M, REINOLD HM, SCHÄFER F, SCHUMACHER K, TIRIER C, URBANITZ D, SUCHY BR AND WAHRlSCH J. (1993). Prognostic value of clinical, laboratory and histological characteristics in multiple myeloma: improved definition of risk groups. Eur. J. Cancer, 29, 978-983.
49. PILARSKI LM, MANT MJ AND RUETHER BA. (1985). Pre-B cells in peripheral blood of multiple myeloma patients. Blood, 66, 416-419.
50. RICCARDI A, GOBBI PG, UCCI G, BERTOLONI D, LUONI R, RUTIGLIANO L AND ASCARI E. (1991). Changing clinical presentation of multiple myeloma. Eur. J. Cancer, 21, 1401-1405.
51. RICCARDI A, MERLINI GP, MONTECUCCO CM, DANOVA M, UCCI G, CASSANO F AND ASCARI E. (1986). Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. Eur. J. Cancer Clin. Oncol., 22, 787-791.
52. SAN MIGUEL JF, MORO MJ AND GONZALEZ M. (1987). Plasmablastic multiple myeloma: an immunological different subtype. (letter). Br. J. Haematol., 66, 275.
53. SUKPANICHNANT S., COUSAR JB, LEELASIRI A, GRABER SE, GREER JP AND COLLINS RD. (1994). Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum. Pathol., 25, 308-318.
54. TRIBALTO M, AMADORI S AND CANTONETTI M. (1985). Treatment of multiple myeloma: a randomized trial of three different regimens. Leuk. Res., 9, 1043-1049.